Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Medicare Part D
Pharma
Teva's subdued outlook puts damper on strong 2024 results
Despite finishing strong in 2024, Teva’s cautious approach to the new year appears to have investors spooked.
Fraiser Kansteiner
Jan 29, 2025 1:13pm
Congress has 'time-limited' chance to fix high drug costs
Jul 14, 2021 10:40am
Revlimid, Eliquis and Eylea top Medicare spending ranks
Mar 15, 2019 9:04am
Trump's budget amps up message on familiar drug pricing goals
Mar 12, 2019 12:16pm
PhRMA ads target proposals to revamp Medicare drug coverage
Mar 11, 2019 10:58am
Big Pharma gave money to patient advocacy groups
Mar 4, 2019 10:44am
